Research programme: multiple sclerosis therapies - Provid

Drug Profile

Research programme: multiple sclerosis therapies - Provid

Alternative Names: PV-072; PV-267

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Provid Pharmaceuticals
  • Developer Provid Pharmaceuticals; University of Texas Health Science Center at San Antonio
  • Class Small molecules
  • Mechanism of Action HLA-DR antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
  • 15 Oct 2013 Preclinical development is ongoing in USA
  • 14 Jan 2004 Provid and Suntory have entered into an agreement to co-develop small peptide mimetic inhibitors of antigen presentation by MHC class II DR2 molecules in the US for multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top